Capital where I sit on the board, advise, or take an operational position. Founded in 2011. Directors: Nathan Buzza and Trudi Buzza.
In one paragraph
Allure Capital is a boutique family-office investment firm I founded in 2011 to do, with my own money, the kind of investing I’d wanted done for me twenty years earlier. The preference is for healthcare, medical-device, and technology businesses with management who have actually shipped, platforms running at live sites, and a path to exit within thirty-six months.
Across fifteen years I’ve reviewed roughly a hundred proposals and invested in a small handful. The list below is what’s active today — deliberately short. The page below it records the engagements that closed.
Investment brief
Sector preference: Healthcare software · medical devices · clinical workflow · AI/ML applied to clinical decision support. Adjacent technology businesses considered.
Cheque size: A$500k – A$5m, with capacity to source larger amounts for syndication.
Stake: Meaningful enough to earn a board seat. Typically 5–15%.
Time horizon: Exit within 36 months of entry; longer if the business is compounding well.
Geography: Australian-listed or unlisted. Cross-border deals welcome where I’ve worked the seam before.
Active today
A deliberately short list. The page below records every closed engagement.
Founder & CEO · 2017–present
Electronic-mentalism business serving working professional performers in 80+ countries. Australian headquarters, engineering distributed across continents. The work itself is not discussed in public. Held for the long arc.
Founder & Director · 2011–present
The family-office vehicle itself. Founded 2011, ACN 152 310 766. Directors: Nathan Buzza & Trudi Buzza. Holds the active positions, sources new opportunities, and underwrites the passive portfolio.
Seed investor
A Sydney-based single-product business making the Halo Digital Goniometer — a clinical-grade joint range-of-motion device validated by UWA, UCSF, UNSW and Bond University. Founder Hayley Saddington/Warren. Held since seed round.
Past engagements
Board roles and advisory engagements held under the Allure mandate, since closed. Listed for the record.
Non-Executive Director · 2017–20
Machine-learning cough diagnosis built on UQ research originally funded by the Bill & Melinda Gates Foundation. Acquired by Pfizer in September 2022 at A$0.208/share. 83% shareholder approval.
Executive Director · 2014–17
Backed the reverse takeover of Naracoota Resources to list Alcidion on the ASX in December 2015. Initial scrip plus revenue-milestone tranches. Co-investors: BlueSky PE, Patersons. Today the Miya Precision platform runs in 400+ hospitals globally. Resigned as director and divested.
Major shareholder & VP, Austco Communications · 2012–14
Underwrote the rights issue, became the second-largest shareholder, and rejoined Austco alongside founder Bob Grey to drive the turnaround. (The parent company was listed as Azure Healthcare at the time; the business has since been renamed Austco Healthcare — one and the same company.) Share price moved from 3.3¢ to ~34¢ over 2.5 years — a 1,200% / 12× return. Exited April 2014.
Board Advisor · sale on behalf of shareholders
Invited back to the firm where I’d started as a seventeen-year-old software engineer. Joined the board as advisor and led the successful sale of the business on behalf of the shareholders.
Founder, CEO & Chief Technologist · 1992–2010
The original engagement, predating Allure. Founded with A$5,200 in a Mosman Park shed. Sold to Amcom Software in October 2008. Rolled into USA Mobility (now Spok) in 2011.
“It was only once Buzza (and founder Robert Grey) both rejoined the company that its fortunes turned around.”
Claude Walker · Ethical Equities · 30 April 2014 · on Azure Healthcare (ASX:AZV)
Seven criteria
Verbatim from the Allure Capital investment thesis, July 2016. Unchanged since.
The other half of the family office
See the passive portfolio →